New hope for stubborn muscle weakness: tofacitinib shows promise
NCT ID NCT04431895
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times
Summary
This study tested a drug called tofacitinib in 19 adults with myasthenia gravis that did not improve with standard treatments. Participants took a 5 mg tablet twice daily for 4 months, then stopped for 1 month. The goal was to see if the drug could reduce muscle weakness and improve daily activities. Since myasthenia gravis often requires ongoing medication, this approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.